A Phase 3 interventional study of Rosuvastatin and Simvastatin in Fredrickson Type IIa & Type IIb Dyslipidaemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing rosuvastatin in Dyslipidemias — 2 open to participants now, 2 under way, none of them phase 3. rosuvastatin · Dyslipidemias.
Among the 42 studies testing rosuvastatin in Dyslipidemias, this one is the 8th largest by enrollment, is one of 5 that started in 2002, is one of 14 in phase 3, and was the 8th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →2 of the 42 studies testing rosuvastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
Taipei Medical University WanFang Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 442 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 128 across the 42 interventional studies. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 42 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
57 studies in Dyslipidemias by AstraZeneca: 1 open now, 3 under way, 1 of them phase 3. Of 52 finished, 11 (21%) have results posted.
Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2002, is one of 13 in phase 3, and was the 14th registered.
AstraZeneca’s Dyslipidemias studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing rosuvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 57 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa \& Type IIb Dyslipidaemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rosuvastatin
Drug: Rosuvastatin
Simvastatin
Drug: Simvastatin
Also known as: Crestor
Also known as: Zocor
Development of Proteinuria
Time frame: 2 weekly
Renal effects of rosuvastatin and simvastatin
Time frame: 2 weekly
Low density lipoproteins cholesterol levels
Time frame: 2 weekly
Safety: adverse events & abnormal laboratory markers
Time frame: 2 weekly
No study locations are listed for this record.
The record gives a start of Sep 2002 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin